Fulgent Genetics (FLGT) Cash from Operations (2015 - 2026)

Fulgent Genetics has disclosed Cash from Operations across 12 years of filings, most recently posting -$23.8 million for Q2 2026.

• In Q2 2026, Cash from Operations rose 21.26% year-over-year to -$23.8 million; the TTM figure through Jun 2026 stood at -$83.7 million (down 233.55% YoY), while the FY2025 annual figure was -$101.6 million, down 582.61% from the prior year.
• Cash from Operations came in at -$23.8 million for Q2 2026 at Fulgent Genetics, down from $7.1 million in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of $188.4 million in Q1 2022 to a low of -$78.1 million in Q4 2025.
• Average Cash from Operations over 5 years is $10.2 million, with a median of $8.5 million recorded in 2023.
• Year-over-year, Cash from Operations sank 804.11% in 2025 and surged 260.17% in 2026.
• Over 5 years, Cash from Operations stood at $33.2 million in 2022, then slumped by 55.03% to $14.9 million in 2023, then surged by 67.53% to $25.0 million in 2024, then slumped by 412.35% to -$78.1 million in 2025, then jumped by 69.6% to -$23.8 million in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were -$23.8 million in Q2 2026, $7.1 million in Q1 2026, and -$78.1 million in Q4 2025.